Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019

Detalhes bibliográficos
Autor(a) principal: Castaldelli-Maia, João M.
Data de Publicação: 2020
Outros Autores: Wang, Yuan-Pang, Brunoni, Andre R., Faro, Andre, Guimarães, Rafael A., Lucchetti, Giancarlo, Martorell, Miquel, Moreira, Rafael S., Pacheco-Barrios, Kevin, Rodriguez, Jefferson A. B., Roever, Leonardo, Silva, Diego A. S., Tovani-Palone, Marcos R., Valdez, Pascual R., Zimmermann, Ivan R., Culbreth, Garland T., Hay, Simon I., Murray, Christopher J. L., Bensenor, Isabela M.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da FIOCRUZ (ARCA)
Texto Completo: https://www.arca.fiocruz.br/handle/icict/42760
Resumo: Coordenac¸ão de Aperfeic¸oamento de Pessoal de Nı´vel Superior - Brasil (CAPES) [Finance Code 001], Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico [439967/2016-3], Programa de Excelência em Pesquisa [420765/ 2017-4] and Financiadora de Estudos e Projetos [MCTIC/FINEP/FNDCT 01/2016 ZIKA – 0416006000]. AB and MB-N are CNPq fellows.
id CRUZ_f4090cfb5837295edb6633d8f5bce291
oai_identifier_str oai:www.arca.fiocruz.br:icict/42760
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Castaldelli-Maia, João M.Wang, Yuan-PangBrunoni, Andre R.Faro, AndreGuimarães, Rafael A.Lucchetti, GiancarloMartorell, MiquelMoreira, Rafael S.Pacheco-Barrios, KevinRodriguez, Jefferson A. B.Roever, LeonardoSilva, Diego A. S.Tovani-Palone, Marcos R.Valdez, Pascual R.Zimmermann, Ivan R.Culbreth, Garland T.Hay, Simon I.Murray, Christopher J. L.Bensenor, Isabela M.2020-08-14T13:06:13Z2020-08-14T13:06:13Z2023CASTALDELLI-MAIA, João M. et al. Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019. The lancet. Psychiatry, v. 10, n. 2, p. 85-97, Feb. 2023.2215-0366https://www.arca.fiocruz.br/handle/icict/4276010.1016/S2215-0366(22)00339-XCoordenac¸ão de Aperfeic¸oamento de Pessoal de Nı´vel Superior - Brasil (CAPES) [Finance Code 001], Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico [439967/2016-3], Programa de Excelência em Pesquisa [420765/ 2017-4] and Financiadora de Estudos e Projetos [MCTIC/FINEP/FNDCT 01/2016 ZIKA – 0416006000]. AB and MB-N are CNPq fellows.The Bill & Melinda Gates Foundation.University of São Paulo. Department of Psychiatry. São Paulo, SP, Brazil / Department of Epidemiology. Mailman School of Public Health. Columbia University. New York, NY, USA / Department of Medical Psychology. School of Medical Sciences. National University of Asuncion. San Lorenzo, Paraguay / Department of Neuroscience. Medical School. FMABC University Centre. Santo André, SP, Brazil.University of São Paulo. Department of Psychiatry. São Paulo, SP, Brazil.University of São Paulo. Department of Psychiatry. São Paulo, SP, Brazil / University of São Paulo. Department of Internal Medicine. São Paulo, SP, Brazil.Federal University of Sergipe. Department of Psychology. São Cristóvão, SE, Brazil.Federal University of Goiás. Faculty of Nursing. Goiânia, GO, Brazil.Federal University of Juiz de Fora. School of Medicine. Juiz de Fora, MG, Brazil.University of Concepción. Department of Nutrition and Dietetics. Concepción, Chile / University of Concepción. Centre for Healthy Living, Concepción, Chile.Oswaldo Cruz Foundation. Institute Aggeu Magalhães. Department of Public Health. Recife, PE, Brazil / Federal University of Pernambuco. Recife, PE, Brazil.Harvard University. Spaulding Rehabilitation Hospital. Physical Medicine and Rehabilitatio. Boston, MA, USA / Universidad San Ignacio de Loyola. Vicerrectorado de Investigacion. Lima, Peru.University of Antioquia. Department of Pharmacology and Toxicology. Medellin, Colombia.Federal University of Uberlândia. Department of Clinical Research. Uberlândia, MG, Brazil.Federal University of Santa Catarina. Department of Physical Education. Florianópolis, SC, Brazil.Saveetha Dental College and Hospitals. Saveetha Institute of Medical and Technical Sciences. Chennai, India / Modestum. Eastbourne, UK.Argentine Society of Medicine. Buenos Aires, Argentina / Velez Sarsfield Hospital. Buenos Aires, Argentina.Brasília University. Departamento de Saúde Coletiva. Brasília, DF, Brazil.Institute for Health Metrics and Evaluation. Seattle, WA, USA.Institute for Health Metrics and Evaluation. Seattle, WA, USA / University of Washington. Department of Health Metrics Sciences, School of Medicine. Seattle, WA, USA.University of São Paulo. Department of Internal Medicine. São Paulo, SP, Brazil.Background: South America's substance use profile, poverty, income inequality, and cocaine-supplier role make it a unique place for substance use research. This study investigated the burden of disease attributable to amphetamine use disorder, cannabis use disorder (CAD), cocaine use disorder, and opioid use disorder (OUD) in South America from 1990 to 2019, on the basis of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Methods: GBD 2019 estimated the incidence, prevalence, mortality, years of life lost (YLL), years of life lived with disability (YLD), and disability-adjusted life-years (DALYs) due to substance use disorders in each of the 12 South American countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Guyana, Paraguay, Peru, Suriname, Uruguay, and Venezuela). Data were modelled using standardised tools (ie, the Cause of Death Ensemble model, spatio-temporal Gaussian process regression, and disease modelling meta-regression) to generate estimates of each quantity of interest by sex, location, and year. The analysis included comparisons by sex and country, and against regional and global estimates. Findings: In 2019, the highest amphetamine use disorder burden per 100 000 population in South America was in Peru (66 DALYs). CAD DALY rates per 100 000 in South America were stable between 1990 and 2019, except in Chile and Colombia, which had the highest rates in 2019 (19 DALYs for Chile and 18 DALYs for Colombia). OUD DALYs per 100 000 increased during the period in Brazil and Peru, which in 2019 had the highest rates in South America (82 DALYs for Brazil and 70 DALYs for Peru). In 2019, Brazil had the highest cocaine use disorder DALYs per 100 000 (45 DALYs), nearly double its rate in 1990. DALY rates were higher in males than females for each substance use disorder, except in Paraguay. The overall burden of substance use disorders was higher in males than in females, mainly because of cocaine use disorder and CAD, whereas for amphetamine use disorder, the difference between sexes was minimal, and for OUD there was no difference. For males and females, the highest rate of substance use disorders DALYs per 100 000 was for OUD except in Argentina (in males, 58 DALYs for cocaine use disorder vs 52 DALYs for OUD) and in Paraguay (in females, 77 for amphetamine use disorder vs 50 for OUD). CAD DALY rates were generally the lowest among the substance use disorders for males and females. Amphetamine use disorder YLD rates were reasonably stable throughout the period and were highest in Peru, Paraguay, and Uruguay (>40 YLD per 100 000). For CAD, YLD rates were stable in all countries except Chile and Colombia. Cocaine use disorder YLD rates per 100 000 for the top four countries (Argentina, Uruguay, Chile, and Brazil) increased from 1990 to 2010 (eg, from 19 to 33 in Brazil), but decreased between 2010 and 2019 (eg, from 36 to 31 in Chile). For OUD, YLD rates showed a slight increase in most countries apart from Brazil, which increased from 52 in 1990 to 80 in 2019 and was top among the countries. Amphetamine use disorder YLL rates per 100 000 were highest in Suriname and Peru during the period, although in Suriname it increased from 2·7 in 2010 to 3·2 in 2019, whereas in Peru it decreased from 2·1 to 1·7. The highest YLL rate for cocaine use disorder was in Brazil, which increased from 3·7 in 1990 to 18·1 in 2019. Between 2000 and 2019, Chile and Uruguay showed the highest OUD YLL rates (11·6 for Chile and 10·9 for Uruguay). A high incidence of CAD was found in Chile, Colombia, Guyana, and Suriname. There were high incidences of amphetamine use disorder in Paraguay, cocaine use disorder in Argentina, and OUD in Ecuador. A decrease in annual prevalence for substance use disorders during the period was observed in Venezuela (amphetamine use disorder, CAD, and OUD), Brazil (CAD and amphetamine use disorder), Colombia (amphetamine use disorder and cocaine use disorder), Peru (amphetamine use disorder and cocaine use disorder), Chile and Suriname (amphetamine use disorder), Uruguay (CAD), and Bolivia (OUD). Overall, the cocaine use disorder burden stabilised then decreased. OUD was less prevalent than other substance use disorders but its burden was the highest. Interpretation: The decrease in the burden of cocaine use disorder probably reflects the success of national standardised treatment programmes. Programmes for amphetamine use disorder, CAD, and OUD management should be improved. We did not find an increase in CAD burden in Uruguay, the country with the highest degree of cannabis decriminalisation in the region. Countries in South America should improve monitoring of substance use disorders, including regular surveys to provide more accurate data on which to base policy decisions.engElsevierBurden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleBurden of diseaseCannabis use disorder (CAD)Opioid use disorder (OUD)Disorder burdenAmphetamineinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALve_João_Castaldelli-Maia_IAM_2023.pdfve_João_Castaldelli-Maia_IAM_2023.pdfapplication/pdf1286096https://www.arca.fiocruz.br/bitstream/icict/42760/2/ve_Jo%c3%a3o_Castaldelli-Maia_IAM_2023.pdff551b8dffba71154c1c9924224b2ffc0MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/42760/1/license.txt5a560609d32a3863062d77ff32785d58MD51icict/427602023-06-19 21:41:00.085oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-06-20T00:41Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
title Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
spellingShingle Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
Castaldelli-Maia, João M.
Burden of disease
Cannabis use disorder (CAD)
Opioid use disorder (OUD)
Disorder burden
Amphetamine
title_short Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
title_full Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
title_fullStr Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
title_full_unstemmed Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
title_sort Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990–2019: a systematic analysis of the Global Burden of Disease Study 2019
author Castaldelli-Maia, João M.
author_facet Castaldelli-Maia, João M.
Wang, Yuan-Pang
Brunoni, Andre R.
Faro, Andre
Guimarães, Rafael A.
Lucchetti, Giancarlo
Martorell, Miquel
Moreira, Rafael S.
Pacheco-Barrios, Kevin
Rodriguez, Jefferson A. B.
Roever, Leonardo
Silva, Diego A. S.
Tovani-Palone, Marcos R.
Valdez, Pascual R.
Zimmermann, Ivan R.
Culbreth, Garland T.
Hay, Simon I.
Murray, Christopher J. L.
Bensenor, Isabela M.
author_role author
author2 Wang, Yuan-Pang
Brunoni, Andre R.
Faro, Andre
Guimarães, Rafael A.
Lucchetti, Giancarlo
Martorell, Miquel
Moreira, Rafael S.
Pacheco-Barrios, Kevin
Rodriguez, Jefferson A. B.
Roever, Leonardo
Silva, Diego A. S.
Tovani-Palone, Marcos R.
Valdez, Pascual R.
Zimmermann, Ivan R.
Culbreth, Garland T.
Hay, Simon I.
Murray, Christopher J. L.
Bensenor, Isabela M.
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Castaldelli-Maia, João M.
Wang, Yuan-Pang
Brunoni, Andre R.
Faro, Andre
Guimarães, Rafael A.
Lucchetti, Giancarlo
Martorell, Miquel
Moreira, Rafael S.
Pacheco-Barrios, Kevin
Rodriguez, Jefferson A. B.
Roever, Leonardo
Silva, Diego A. S.
Tovani-Palone, Marcos R.
Valdez, Pascual R.
Zimmermann, Ivan R.
Culbreth, Garland T.
Hay, Simon I.
Murray, Christopher J. L.
Bensenor, Isabela M.
dc.subject.en.pt_BR.fl_str_mv Burden of disease
Cannabis use disorder (CAD)
Opioid use disorder (OUD)
Disorder burden
Amphetamine
topic Burden of disease
Cannabis use disorder (CAD)
Opioid use disorder (OUD)
Disorder burden
Amphetamine
description Coordenac¸ão de Aperfeic¸oamento de Pessoal de Nı´vel Superior - Brasil (CAPES) [Finance Code 001], Conselho Nacional de Desenvolvimento Cientı´fico e Tecnolo´gico [439967/2016-3], Programa de Excelência em Pesquisa [420765/ 2017-4] and Financiadora de Estudos e Projetos [MCTIC/FINEP/FNDCT 01/2016 ZIKA – 0416006000]. AB and MB-N are CNPq fellows.
publishDate 2020
dc.date.accessioned.fl_str_mv 2020-08-14T13:06:13Z
dc.date.available.fl_str_mv 2020-08-14T13:06:13Z
dc.date.issued.fl_str_mv 2023
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv CASTALDELLI-MAIA, João M. et al. Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019. The lancet. Psychiatry, v. 10, n. 2, p. 85-97, Feb. 2023.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/42760
dc.identifier.issn.pt_BR.fl_str_mv 2215-0366
dc.identifier.doi.none.fl_str_mv 10.1016/S2215-0366(22)00339-X
identifier_str_mv CASTALDELLI-MAIA, João M. et al. Burden of disease due to amphetamines, cannabis, cocaine, and opioid use disorders in South America, 1990-2019: a systematic analysis of the Global Burden of Disease Study 2019. The lancet. Psychiatry, v. 10, n. 2, p. 85-97, Feb. 2023.
2215-0366
10.1016/S2215-0366(22)00339-X
url https://www.arca.fiocruz.br/handle/icict/42760
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv Elsevier
publisher.none.fl_str_mv Elsevier
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/42760/2/ve_Jo%c3%a3o_Castaldelli-Maia_IAM_2023.pdf
https://www.arca.fiocruz.br/bitstream/icict/42760/1/license.txt
bitstream.checksum.fl_str_mv f551b8dffba71154c1c9924224b2ffc0
5a560609d32a3863062d77ff32785d58
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324784305537024